Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. and reminds investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [2][4]. Group 1: Allegations Against Atara Biotherapeutics - The complaint alleges that Atara and its executives violated federal securities laws by making false and/or misleading statements regarding manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of the tabelecleucel BLA unlikely [4][9]. - It is claimed that the regulatory prospects of tabelecleucel were overstated, and the manufacturing issues subjected Atara to heightened regulatory scrutiny, jeopardizing ongoing clinical trials [4][9]. - The allegations suggest that these issues were likely to have a significant negative impact on Atara's business and financial condition, rendering the defendants' public statements materially false and/or misleading [4][9]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the EBVALLO™ (tabelecleucel) BLA, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share on January 12, 2026 [5][9]. Group 3: Legal Proceedings - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will direct and oversee the litigation on behalf of the putative class [6]. - Any member of the putative class may move the Court to serve as lead plaintiff or may choose to remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [2][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Atara and its executives made false statements regarding the regulatory prospects of the tabelecleucel BLA, which were overstated due to manufacturing issues [5]. Group 2: Impact of FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter for the EBVALLO™ BLA, indicating that the application could not be approved in its current form due to inadequacies in the ALLELE trial [6]. - Following the FDA's announcement, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [2][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Atara and its executives made false statements regarding the regulatory prospects of the tabelecleucel BLA, which were overstated due to manufacturing issues [5]. Group 2: Impact of FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter for the EBVALLO™ BLA, indicating that the application could not be approved in its current form due to inadequacies in the ALLELE trial [6]. - Following the FDA's announcement, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [4][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [4][8]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Allegations Against Atara - The complaint alleges that Atara and its executives made false and misleading statements regarding manufacturing issues and the regulatory prospects of their product, tabelecleucel [6]. - Specific allegations include that manufacturing issues and deficiencies in the ALLELE study made FDA approval unlikely, overstating the product's regulatory prospects, and increasing the risk of regulatory scrutiny [6]. - The complaint asserts that these issues would likely have a significant negative impact on Atara's business and financial condition [6]. Group 3: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA regarding the EBVALLO™ Biologics License Application, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share on January 12, 2026 [7].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, Inc. following a significant stock price drop after the FDA's Complete Response Letter regarding its drug EBVALLO™ [1][3]. Group 1: Company Overview - Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapies for patients with serious diseases [1]. - The company’s stock experienced a dramatic decline of 56.99%, falling $7.79 to close at $5.88 per share on January 12, 2026, after the FDA's announcement [3]. Group 2: FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter (CRL) for its EBVALLO™ Biologics License Application (BLA) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease [3]. - The CRL indicated that the FDA could not approve the BLA in its current form, citing inadequacies in the evidence of effectiveness from the single arm ALLELE trial [3].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Atara Biotherapeutics, following a significant stock price drop after the FDA's Complete Response Letter regarding its EBVALLO™ treatment [1][3]. Group 1: Company Overview - Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is under investigation for possible securities fraud or other unlawful business practices [1]. - The company recently faced a setback when the FDA issued a Complete Response Letter for its EBVALLO™ Biologics License Application, indicating that the application could not be approved in its current form [3]. Group 2: FDA Response and Impact - The FDA's Complete Response Letter stated that the single-arm ALLELE trial, previously deemed adequate for the BLA filing, is now considered insufficient for demonstrating effectiveness for accelerated approval [3]. - Following the FDA's announcement, Atara's stock price plummeted by $7.79 per share, a decrease of 56.99%, closing at $5.88 per share on January 12, 2026 [3].

Core Insights - Several companies have experienced significant price changes due to various underlying factors, including corporate developments, industry shifts, and broader economic conditions [5] Company-Specific Summaries - Atara Biotherapeutics, Inc. (Nasdaq: ATRA) saw its price drop by approximately 54% to $6.28, down from a year-high of $19.14, potentially due to concerns over trial results, regulatory hurdles, or financial sustainability, particularly after receiving a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application for EBVALLO™ [1][6] - Nuvation Bio Inc. (NUVB-WT) experienced a nearly 47% decrease in price to $0.09, reflecting investor skepticism possibly due to challenges in its oncology-focused pipeline and a lack of recent positive news [2][6] - Lyra Therapeutics, Inc. (LYRA) witnessed a 46% drop in its price to $2.04, attributed to concerns over the clinical progress of its key product candidates or potential financial constraints impacting its research and development activities [3] - Mingteng International Corporation Inc. (Nasdaq: MTEN) saw its price fall by over 41% to $0.077, possibly related to operational challenges, market competition, or broader economic factors affecting the manufacturing sector, despite announcing an expansion of its strategic collaboration in the new energy vehicle sector [4]